BioCatalystWatch
VIRWorkspace / VIR / OverviewCompany library
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. (VIR)

Website

Price
Market cap
Next catalystExpected Q1 2027Elebsiran and tobevibart — CHD clinical programme · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Elebsiran and tobevibart

HBV RNA transcripts

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

VIR-5818

HER2 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

VIR-5500

PSMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

VIR-5500

PSMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Elebsiran and tobevibart

HBV RNA transcripts

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

VIR-5818

HER2 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

VIR-5500

PSMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

VIR-5500

PSMA × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

VIR-5500

PSMA × CD3

PreINDP1P2P3FilingApproved

VIR-1111

HIV epitopes

PreINDP1P2P3FilingApproved
Tobevibart (VIR-3434)

HBsAg

PreINDP1P2P3FilingApproved
SAR446309

T-cell engager

HER2 × CD3

PreINDP1P2P3FilingApproved
SAR446309

T-cell engager

HER2 × CD3

PreINDP1P2P3FilingApproved

Approved / commercial

Approved

PreINDP1P2P3FilingApproved

History / paused

Elebsiran and tobevibart

HBV RNA

PreINDP1P2P3FilingApproved

Influenza A hemagglutinin

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VIR PR & News

PR & News

VIR SEC archive